Clinical Report: Mechanisms of Natural Products in Atherosclerosis
Background
Atherosclerosis is a leading cause of cardiovascular morbidity and mortality, characterized by lipid accumulation and chronic inflammation. While lipid-lowering therapies have reduced cardiovascular events, residual risk remains significant. The gut microbiota has emerged as a critical factor in AS development, influencing lipid metabolism and inflammatory responses.
Data Highlights
No specific numerical data or trial results were provided in the source material.
Key Findings
Natural products modulate gut microbiota, affecting atherogenesis through multiple pathways.
They reduce trimethylamine/trimethylamine N-oxide production and promote short-chain fatty acid generation.
Natural products improve intestinal barrier integrity and suppress inflammation mediated by TLR4/NF-κB and NLRP3.
Most evidence is derived from animal and in vitro studies, with limited clinical data.
Clinical Implications
Further research is needed to establish standardized preparations and validate causal relationships in clinical settings.
Conclusion
More rigorous clinical trials are necessary to confirm the efficacy of natural products in addressing the gut microbiota's role in atherosclerosis.
Researchers applied the 2016 and 2025 American Society of Echocardiography diastolic function guidelines to 87,724 echocardiograms that met criteria for analysis.
